Navigation Links
Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Date:9/18/2007

KENILWORTH, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) will provide a live audio webcast of a presentation by Alex Kelly, vice president, Investor Relations, speaking about the company at the Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference in London on Sept. 19, 2007, at approximately 9 a.m. (London) (approximately 4 a.m. EDT).

Kelly will be speaking on the company's financial performance and the planned acquisition of Organon BioSciences N.V. (OBS). He may also reiterate the company's outlook, as previously stated in the company's second quarter 10-Q, on the following:

-- Sales of VYTORIN and ZETIA are expected to grow in 2007. However,

there is growing competition for Schering-Plough's key brands;

-- Gross margin for the full year of 2007 is expected to improve versus

2006, primarily as a result of annual cost savings of approximately

$100 million expected from the company's manufacturing streamlining

actions in 2006 and improved product mix. However, gross margin in the

second half of 2007 is expected to be slightly lower than the first

half due to the seasonality of some respiratory products;

-- As Schering-Plough's pipeline continues to progress, the company

expects that the number of patients in its clinical trials will

continue to increase in the remainder of 2007. R&D expenses, excluding

any upfront payments, are expected to continue to grow faster than

adjusted net sales in 2007. Adjusted net sales is defined as net sales

plus an assumed 50 percent of the global cholesterol joint venture net

sales;

-- The company's full-year 2007 tax rate is expected to be in the mid-

teens on a GAAP basis, but vary between quarters depending on the

product and country mix of earnings; and

-- In advance of the planned acquisition of OBS, the company will incur

integration planning-related costs and potential foreign currency-

related activity associated with the purchase. The transaction is

anticipated to be accretive to the company's earnings per share in the

first full year, excluding purchase-accounting adjustments and

acquisition-related costs. The company expects to achieve annual

synergies of $500 million, however, it is expected that it will take

three years from the closing to reach this level of synergies.

A live audio webcast of the presentation will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available later that day.

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sonic Foundry to Webcast Bridge Arch Floating Down Mississippi
2. New Sonic Foundry search engine finds words, phrases in video presentations
3. Sonic Foundry creates search engine for 7,000 expert video presentations
4. InvestMidWest calls for business presentations
5. BxVideo designs Web hosting service for Sonic Foundry media presentations
6. Distance Education Conference Selects Sonic Foundry to Make Keynotes, Panel Presentations Available On-Demand
7. Ethanol plant builder to expand Merrill facility
8. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
9. The state of global biotech: An Ernst & Young perspective
10. Doyle announces new energy, global warming policies
11. Lucigen Corp. enters global licensing agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):